Pharmacy Medical News about Pulmonary Disease, Chronic Obstructive Cholinergic Antagonists

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Statins and cancer risk

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Inhaled anticholinergics and the long-term treatment of chronic obstructive pulmonary disease: Weighing benefits and risks
Clinical Cornerstone, 09/25/09

Hogarth D et al. – A meta–analysis recently published in the Journal of the American Medical Association found an increased risk of nonfatal myocardial infarction, stroke, and cardiovascular death associated with inhaled anticholinergic use in patients with chronic obstructive pulmonary disease (COPD); however, inherent limitations in the meta–analysis and contradictory results from other studies cast uncertainty onto its conclusions. For example, the Understanding Potential Long–term Impacts on Function with Tiotropium trial, a large, prospective, 4–year outcome study in nearly 6000 patients with COPD, did not demonstrate an increase in cardiovascular events with anticholinergic therapy. Until more data are available, clinicians should always carefully weigh safety and efficacy data and help patients make informed decisions about their COPD care.

<< Previous
Disinhibition Due to Disruption of the Orbitofrontal Circuit...

Next >>
Epidemiology of antidepressant medication use in the Canadian...